How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,627 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Where is Hepatitis D? High Prevalence of Hepatitis B/D Coinfection in Central Africa

of hepatitis B/D coinfection in this region, particularly in countries such as Cameroon, Central African Republic and Gabon. In a recently published of nearly 2,000 hepatitis B infected blood samples from 2010-2016 in Cameroon, 46.7% tested positive for hepatitis D antibodies, a marker of past or current hepatitis D coinfection. Another of 233 chronic hepatitis B carriers from 2008-2009 found a 17.6% positivity for hepatitis D antibodies. Other small studies from the Central African Republic have revealed (...) infants will not begin the vaccine series until 6 weeks of age, creating a window for exposure to hepatitis B. Greater than 95% of babies infected with hepatitis B will go on to develop chronic hepatitis B infections, leaving them susceptible to a future hepatitis D infection. Spread the same way as hepatitis B, through direct contact with infected blood and sexual fluids, hepatitis D can be contracted through , blood transfusions, shared razors and unprotected sex. Although the severity of disease

2018 hepbblog

102. Hepatitis B and C testing: people at risk of infection

infectious disease and the Hepatitis B antenatal screening and newborn immunisation programme, both published by the Department of Health, and in the NICE guidance on Reducing the differences in the uptake of immunisations. Whose health will benefit? In the UK, the majority (95%) of new chronic hepatitis B infections occur in migrant populations, having been acquired perinatally in the country of birth. In contrast, approximately 90% of chronic hepatitis C infections are seen in people who inject drugs (...) or have done so in the past. Groups at increased risk of hepatitis B compared with the general UK population include: Hepatitis B and C testing: people at risk of infection (PH43) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 11 of 93People born or brought up in a country with an intermediate or high prevalence (2% or greater) of chronic hepatitis B. This includes all countries in Africa, Asia, the Caribbean

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

103. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management (PubMed)

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr (...) incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

104. Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series (PubMed)

Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series Reactivation of viral hepatitis B (HBV) and C (HCV) has been reported in various case reports of patients with arthritis on biological therapy. The objective of this study was to describe the clinical characteristics and outcomes of arthritis patients with HBV or HCV treated with biological therapy.This is a retrospective case series including all patients above 13 years of age (...) with arthritis patients from four centers in Saudi Arabia with concurrent chronic viral hepatitis infection (HBV or HCV) who received biological agents in the rheumatology clinics during their course of their disease from duration of the disease onset until last outpatient visit up to November 2015. Demographic information, full details about the hepatitis status of each patient, rheumatic disease diagnosis and different therapies used were reviewed.We identified 10 cases each with HBV and HCV on biological

Full Text available with Trip Pro

2017 European journal of rheumatology

105. Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection (PubMed)

Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection Hepatitis B virus (HBV) infection is a serious health threat around the world. Despite the availability of an effective hepatitis B vaccine, the number of HBV carriers is estimated to be as high as 240 million worldwide. Global mortality due to HBV-related liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) may be as high as 1 million deaths per year (...) . HBV is transmitted via blood and body fluids, and is much more infectious than both human immunodeficiency virus (HIV) and hepatitis C virus. While HBV infection exhibits a variety of clinical presentations, even asymptomatic carriers can develop HCC without liver fibrosis. Current therapeutic options against HBV include pegylated interferon (Peg-IFN) and nucleos(t)ide reverse transcriptase inhibitors (NRTIs), with clinical studies showing a significant association between loss of HBV DNA

Full Text available with Trip Pro

2016 Annals of Translational Medicine

106. ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL (PubMed)

ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL According to the guidelines, the viral load of 2,000 IU/mL is considered the level to differentiate between inactive carriers and HBeAg(-) chronic hepatitis B patients. Even so, liver damage may be present in patients with lower viral load levels, mainly related to regional variations. This study aims to verify the presence of liver injury in patients with viral load below 2,000 IU/mL.Patients presenting

Full Text available with Trip Pro

2016 Revista do Instituto de Medicina Tropical de São Paulo

107. Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study

is that these can be determined by prospective follow-up of a population-based cohort. Aims, purpose, or objectives: To determine the characteristics of a population of asymptomatic Cameroonian adults who work for the Cameroon Baptist Convention Health Board (CBCHB) who have chronic hepatitis B infection. To determine the phase of infection into which these Hepatitis B carriers fall. To determine the incidence and risk factors for cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma in this cohort (...) ) related information: Groups and Cohorts Go to Group/Cohort hepatitis B cohort CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening Outcome Measures Go to Primary Outcome Measures : Proportion of subjects in each phase of chronic hepatitis B infection at enrollment [ Time Frame: Enrollment ] distribution of subjects across the 4 phases of chronic hepatitis B at enrollment (immune tolerant, immune clearance, inactive carrier, and reactivation phases

2016 Clinical Trials

108. Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration

Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02953600 Recruitment Status : Unknown Verified October 2016 by Taipei Medical University WanFang Hospital

2016 Clinical Trials

109. Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. (PubMed)

Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disorder with progressive weakness. Acute-onset CIDP resembles Guillain-Barre syndrome (GBS), a rapidly progressive disorder, and follows a chronic course. To our knowledge, no case of acute-onset CIDP in hantavirus and hepatitis B virus (HBV) coinfection has been reported previously.We (...) report a case of acute-onset CIDP that was initially diagnosed as GBS.A 44-year-old male logger complained of acute quadriplegia and dyspnea. Mechanical ventilation was initiated. He was an HBV carrier with mild elevation of hepatic enzyme, and positive for hantavirus antibody. He was diagnosed with GBS and immunoglobulin therapy was administered.After 8 months, quadriplegia and hypesthesia recurred. Immunoglobulin therapy at this time had no effect, but steroid therapy had some effect.A diagnosis

Full Text available with Trip Pro

2016 Medicine

110. Association of chronic hepatitis B virus infection with preterm birth: our experience and meta-analysis. (PubMed)

Association of chronic hepatitis B virus infection with preterm birth: our experience and meta-analysis. To assess the association of chronic hepatitis B virus (HBV) infection with preterm birth (PTB).A cohort of 20,498 pregnant women (497 HBV carriers with 20,001 non-HBV controls) with normal alanine aminotransferase (ALT) levels was selected from the Obstetrics & Gynecology Hospital of Nantong University. The clinical parameters and PTB incidence were compared between HBV carriers and non-HBV (...) subjects. For the meta-analysis, we searched the PubMed, Ovid and Cochrane Library databases for studies comparing PTB incidence between individuals with chronic HBV infection and non-HBV subjects.HBV carriers were slightly older and had slightly higher ALT levels within normal limits. The body mass index, education and history of pregnancy between HBV carrier and non-HBV groups were comparable. PTB incidence was not associated with HBV carrier status [relative risk (RR) 0.98, 95% confidence interval

2016 Journal of perinatal medicine

111. Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics…

it’s been around ten years later are the chances of me having it low as it hasn’t came up yet? I know it can lay dormant but not sure how long for Hello: Though not advisable, there is a low chance that you became infected. If you became infected at that time, your prior test for hepatitis B would have shown signs of infection. If you are concerned, please get tested again and also get vaccinated so you are forever protected against hepatitis B. Good luck. Hi, I am chronic hepa B carrier since 2014 (...) Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the HBV Basics… Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the Hep B Basics - Hepatitis B Foundation , Newly Diagnosed with Hepatitis B? Acute or Chronic? Learning the Hep B Basics Image courtesy of dream designs at FreeDigitalPhotos.net If you’ve just been diagnosed with hepatitis B after a routine blood test or following a , you may be feeling overwhelmed with information about this complicated infection

2016 hepbblog

112. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. (PubMed)

Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. Interleukin-33 (IL-33) and ST2 have been demonstrated to be associated with liver damage. However, their potential value in hepatitis B virus (HBV) infection remains unknown. This study was designed to investigate the change of serum IL-33 and ST2 levels in the natural course of chronic HBV infection.A total of 120 patients with chronic hepatitis B (CHB), 20 chronic hepatitis B virus (...) of ALT, IL-33 and ST2 were compared between patients with HBeAg-positive CHB and HBeAg-negative CHB.Our study revealed that the serum levels of IL-33 and ST2 varied in different courses of chronic hepatitis B virus infection. The serum levels of IL-33 and ST2 elevated as serum ALT levels increased in patients with CHB. They might indicate liver damage for patients with CHB, just like ALT.

Full Text available with Trip Pro

2016 BMC Infectious Diseases

113. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil (PubMed)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including (...) . The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective.

Full Text available with Trip Pro

2016 Memórias do Instituto Oswaldo Cruz

114. T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection (PubMed)

, chronic hepatitis B (CHB) patients, as well as asymptomatic HBV carriers (ASCs). We observed dynamic changes of T-bet, PD-1, IFN-γ and perforin in acute stage and recovery stage of acute hepatitis B (AHB).Comparing with other cohorts, HBV-specific CD8+ T cells from rAHB demonstrated a superior ability in T-bet, IFN-γ and perforin expression, but an inferior ability in PD-1 expression. In the CHB group, the level of T-bet has a linear relationship with the level of PD-1, IFN-γ and HBV DNA, respectively (...) T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection The mechanisms leading to virus-specific CD8+ T cell dysfuction in chronic hepatitis B virus (HBV) infection remain to be elucidated. Our study focused on the role of transcription factor T-bet in HBV infection because it is a crucial regulator of T cell immunity.We assessed the expression of T-bet along with PD-1, IFN-γ and perforin, in HBV-specific CD8+ T cells from resolved acute hepatitis B (rAHB) patients

Full Text available with Trip Pro

2016 Virology journal

115. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus (PubMed)

Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus Chronic infection with hepatitis B virus (HBV) occurs in approximately 6% of the world's population. Carriers of the virus are at risk for life-threatening complications, and developing curative treatment remains a priority. The main shortcoming of licensed therapies is that they do not affect viral covalently closed circular DNA (cccDNA), a stable intermediate of replication. Harnessing gene editing

Full Text available with Trip Pro

2016 Molecular Therapy

116. Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You?

Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You? Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You? - Hepatitis B Foundation , , , Diagnosed With Chronic Hepatitis B? What Does Your HBV DNA Test Tell You? Image courtesy of Praisaeng, at FreeDigitalPhotos.net. If you have been diagnosed with chronic hepatitis B, your doctor has probably run several that show if the infection is harming your liver and identify what stage of infection you (...) test. Labs usually measure down to less than 200 IU/mL. Below the threshold, the viral load is considered “undetectable” – something everyone with chronic hepatitis B wants to hear. How HBV DNA results are presented mathematically on your lab report can be confusing. Because the amount of virus in the blood may be very high – in the millions or billions – the result may be displayed as an exponent or a log, rather than a whole number. You may need to convert these numbers to fully understand them

2016 hepbblog

117. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey (PubMed)

Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors.This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral (...) therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant.Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males

Full Text available with Trip Pro

2016 Health and quality of life outcomes

118. Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection (PubMed)

Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection There are ~350 million chronic carriers of hepatitis B (HBV). While a prophylactic vaccine and drug regimens to suppress viremia are available, chronic HBV infection is rarely cured. HBV's limited host tropism leads to a scarcity of susceptible small animal models and is a hurdle to developing curative therapies. Mice that support engraftment with human hepatoctyes have

Full Text available with Trip Pro

2016 Virology

119. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study (PubMed)

Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study Whether the progression of advanced pancreatic ductal adenocarcinoma (PDAC) patients could be affected by HBV exposure remains to be determined. Therefore, we conducted this study to assess the effect of HBV infection on PDAC progression among a large cohort in China.A multicenter cohort study was conducted to explore whether (...) liver metastasis and overall survival in locally advanced and metastatic PDAC could be affected by HBV infection. In this study, we collected 1,526 advanced PDAC patients at three participating hospitals - Shanghai Cancer Center, Changhai Hospital and Ruijin Hospital from 2004 to 2013. The association between HBV status and advanced PDAC progression was then examined.In multivariable Logistic regression model, chronic hepatitis B(CHB) infection was inversely associated with synchronous liver

Full Text available with Trip Pro

2016 Oncotarget

120. Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report (PubMed)

Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report Alpha-fetoprotein is produced by a variety of tumors such as hepatocellular carcinoma, hepatoblastoma, and germ cell tumors of the ovary and testes. However, we present a case of significantly elevated serum alpha-fetoprotein without evidence of malignant disease in a patient who is a carrier of chronic hepatitis B.A 60-year-old Korean man presented with markedly increased (...) patient was diagnosed with acute exacerbation of chronic hepatitis B, and we presumed that this condition might be related to extremely elevated alpha-fetoprotein. When our patient was treated with entecavir, the serum alpha-fetoprotein level immediately decreased, in parallel with the hepatitis B virus deoxyribonucleic acid copy number.We report a rare case of extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without any malignancy, and a decrease in this tumor

Full Text available with Trip Pro

2016 Journal of medical case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>